PDE4 inhibitors in COPD - A more selective approach to treatment

Respiratory Medicine

Volumn 98, Issue 6, 2004, Pages 495-503

  Vignola, Antonio Maurizio ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Anti inflammatory; Chronic obstructive pulmonary disease; Cilomilast; Phosphodiesterase 4 inhibitors; Theophylline

Indexed keywords

CARBAMAZEPINE; CILOMILAST; CIMETIDINE; CIPROFLOXACIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ENOXACIN; ERYTHROMYCIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; ISOPRENALINE; MEXILETINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROPAFENONE; PROPRANOLOL; RIFAMPICIN; ROFLUMILAST; ROLIPRAM; THEOPHYLLINE; TOBACCO SMOKE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CATECHOLAMINE BLOOD LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMA; CONVULSION; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INSOMNIA; LEUKOCYTOSIS; LUNG FUNCTION; METABOLIC DISORDER; NAUSEA; NONHUMAN; PATHOGENESIS; PEAK EXPIRATORY FLOW; PHYSICIAN; PLASMA CLEARANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; STOMACH ACID SECRETION; TACHYCARDIA; VOMITING;

EID: 2542575493     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.12.012     Document Type: Article

References (67)

1. Giembycz MA. Cilomilast: a breath of relief? Trends Mol Med 2001;7:433-4.
2. World Health Organization. The world health report. 1997. Available at: http://www.who.int/whr2001/2001/archives/1997/index.htm
3. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001;10: 1361-79.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease study. Lancet 1997;349:1498-504.
5. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996;274: 740-3.
6. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report 2001 (Updated 2003). 2003.
8. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:347-60.
9. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
10. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8.
11. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
12. Hay DW. Chronic obstructive pulmonary disease: emerging therapies. Curr Opin Chem Biol 2000;4:412-9.
13. Barnette MS, Underwood DC. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 2000;6:164-9.
14. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5.
15. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164: S28-38.
16. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
17. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Natl Rev Mol Cell Biol 2002; 3:710-8.
18. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-70.
19. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-80.
20. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002;121:192S-6S.
21. Teixeira MM, Gristwood RW, Cooper N, et al. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997;18:164-71.
22. Barnette MS, Christensen SB, Essayan DM, et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998;284:420-6.
23. Spina D, Landells LJ, Page CP. The rote of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 1998;28(Suppl 3):24-34.
24. Peleman RA, Kips JC, Pauwels RA. Therapeutic activities of theophylline in chronic obstructive pulmonary disease. Clin Exp Allergy 1998;28(Suppl 3):53-6.
25. Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1371-6.
26. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-8.
27. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991;46: 512-23.
28. Dent G, Giembycz MA. Phosphodiesterase inhibitors: lily the pink's medicinal compound for asthma? Thorax 1996;51: 647-9.
29. Church MK, Featherstone RL, Cushley MJ, et al. Relationships between adenosine, cyclic nucleotides, and xanthines in asthma. J Allergy Clin Immunol 1986;78:670-5.
30. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99:8921-6.
31. Giembycz MA, Dent G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy 1992;22:337-44.
32. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90.
33. Schudt C, Gantner F, Tenors H, et al. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther 1999;12:123-9.
34. Underwood DC, Bochnowicz S, Osborn RR, et al. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 1998;287:988-95.
35. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79.
36. Baumer W, Gorr G, Hoppmann J, et al. Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis. Eur J Pharmacol 2002;446:195-200.
37. Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003;58:573-9.
38. Kohyama T, Liu X, Zhu YK, et al. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen get degradation induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol 2002;27: 487-94.
39. Kohyama T, Liu X, Wen FQ, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002;26:694-701.
40. Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 2003.
41. Au BT, Teixeira MM, Collins PD, et al. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 1998;123:1260-6.
42. Cazzola M, Donner CF, Matera MG. Long acting beta-2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999;54:730-6.
43. Hendeles L, Weinberger M. Theophylline. A state of the art review. Pharmacotherapy 1983;3:2-44.
44. Gomm PJ, Osselton MD, Broster CG, et al. The effect of salbutamol on breath alcohol testing in asthmatics. Med Sci Law 1991;31:226-8.
45. Cooling DS. Theophylline toxicity. J Emerg Med 1993;11: 415-25.
46. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-38.
47. Ohnishi A, Kato M, Kojima J, et al. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging 2003;20:71-84.
48. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988;297:1506-10.
49. Zussman BD, Benincosa LJ, Webber DM, et al. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol 2001;41: 950-8.
50. Ohnishi A. A review of clinical use of theophylline in acute asthma: factors influencing kinetic disposition and drug interactions. Methods Find Exp Clin Pharmacol 2000;22: 253-8.
51. Jonkman JH. Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Allergy Clin Immunol 1986;78:736-42.
52. Jonkman JH, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984;9:309-34.
53. Zussman BD, Davie CC, Kelly J, et al. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy 2001;21:653-60.
54. Simon PM, Statz EM. Drug treatment of COPD. Controversies about agents and how to deliver them. Postgrad Med 1992; 91:473-9.
55. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358: 265-70.
56. Edelson JD, Compton C, Nieman R, et al. Cilomilast (Ariflo) 15 mg BID safety in a 6-month clinical trial program. Am J Respir Crit Care Med 2001;163 (Suppl):A771.
57. Edelson JD, Compton C, Nieman R, et al. Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: results of a 6-month trial. Am J Respir Crit Care Med 2001;163 (Suppl):A277.
58. Zhu J, Anderson K, Vleisides T, et al. The positive effect of cilomilast on lung function in patients with chronic obstructive pulmonary disease (COPD) is independent of patient smoking status. Eur Respir J 2002;20 (Suppl 38):620s.
59. Leitchl S, Syed J, Bredenbroker D, et al. Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165 (Suppl):A229.
60. Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991;99:1415-20.
61. Bredenbroker D, Syed J, Leitchl S, et al. Safety of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD. Am J Respir Crit Care Med 2002;165(Suppl):A595.
62. Drollman A, Hartmann M, Zech K, et al. Patients with severe renal impairment do not require dose adjustment of roflumilast. Eur Respir J 2002;20(Suppl 38):P743.
63. Hünnemeyer A, Hauns B, Drollman A, et al. Pharmacokinetics of roflumitast and its active metabolite roflumilast-N-oxide is not influenced by smoking. Am J Respir Crit Care Med 2002;165(Suppl):A594.
64. Manegold A, Hunnemeyer A, Zech K, et al. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in middle aged and young subjects. Eur Respir J 2002; 20(Suppl 38):P744.
65. Weimar C, Bethke T, Westphal K, et al. Roflumilast and its active metabolite, roflumilast N-oxide, do not interact with inhaled salbutamol. Am J Respir Crit Care Med 2002; 165(Suppl):A594.
66. Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition. Clin Pharmacol Ther 1976;19: 546-51.
67. Hendeles L, Massanari M, Weinberger M. Update on the pharmacodynamics and pharmacokinetics of theophylline. Chest 1985;88:103S-11S.